2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2805 Improving treatment access for myeloma patients with outpatient bispecific antibody step-up-dosing programs

Sandra Mazzoni, DO, Jack Khouri, MD2, Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO3, Christy Samaras, DO4, Faiz Anwer, MD5, Shahzad Raza, MD6, Louis Samuel Williams, MD7, Diana Basali, MD8, Mikhaila Rice, PharmD9, Jason Valent, MD10
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States

Background: Treatment for multiple myeloma (MM) is rapidly evolving in the era of cell therapy, with safety and efficacy data supporting T-cell redirecting bispecific antibodies in earlier lines of therapy, which will soon include the front-line setting. These drugs lead to rapid responses with median time to first response around 1.0-1.7 months, but safety concerns exist with ~70% CRS risk during step-up dosing (SUD). There are also logistical issues regarding SUD administration and access to these treatments remain limited due to the distance many patients live from centers administering SUD.

Initially, SUD was performed in the inpatient setting at academic centers. In recent years, many academic centers transitioned to outpatient SUD, often using a third-party company to monitor vital signs for evidence of CRS and hiring of additional staff to support these programs. With our outpatient SUD program our goal was to develop a safe protocol using our existing staff and resources that are available at most community practices. This program could then be implemented in the setting where many myeloma patients receive care, their local community oncology practice.

Methods: To qualify for our outpatient SUD program a patient must live or be housed within 30 minutes of our treatment center and have a 24-7 caregiver with them through the duration of SUD, which can be up to 10 days. The patient cannot have rapid disease progression or a large burden of extramedullary disease, to avoid any rare issues with tumor lysis or the potential increased risk of severe CRS.

Education is provided to both the patient and their caregiver regarding CRS and ICANs. We used the Immune Effector Cell Encephalopathy (ICE) score to assess for ICANs. “Pocket Dex” is given with instructions to take 12 mg if a fever develops, then to immediately call. During office hours our nurses handle the calls and after-hours calls are answered by our fellows. If a fever persists after 2 hours despite the use of “Pocket Dex”, by protocol patients are directed to the ED for admission.

We give prophylactic tocilizumab (8 mg/kg, max dose 800 mg) an hour prior to the initial SUD and common premeds including dexamethasone 16 mg, diphenhydramine 50 mg and acetaminophen 650 mg with each SUD. We provide SUD on Mondays and Wednesdays to avoid CRS over the weekend. A brief 10-minute provider pre-treatment visit occurs prior to each SUD to verify understanding of the protocols around CRS and ICANs, obtain an ICE score and confirm no ongoing toxicities. Our nurses call the patient on non-treatment weekdays to re-educate around CRS and ICANs, and verify there are no un-reported concerning signs or symptoms. Initially, we asked patients to present to a fellow-based clinic for symptom assessment on Saturdays as a safety-net.

For infection prophylaxis all patients remained on shingles prophylaxis and received both IVIG 0.4 g/kg every 28 days and PJP prophylaxis with sulfamethoxazole/trimethoprim DS as the preferred agent.

Results: Thirteen patients, 7 teclistamab, 5  talquetamab and 1 elranatamab, received SUD in the first 3 months of the outpatient program. All patients remained safely outpatient during SUD, with no occurrence of CRS or ICANs. There were no dose delays. Three patients required local housing arrangements. We received only one after-hours patient call regarding chest pain. The patient was directed to the main campus ED with work up confirming non-cardiac etiology and discharged safely home with resolution of symptoms. Limiting factors of the program included housing needs which could require financial assistance and lack of care giver support.

Conclusions: Our program was initially designed to minimize additional resources yet balance potential safety issues. We have learned that the use of prophylactic tocilizumab given 1 hour prior + dexamethasone pre-med has thus far prevented CRS and ICANs for this cohort of patients. We plan to safely liberalize the program by offering SUD on Monday through Thursdays, which based on our data will still avoid any potential CRS on weekends. We will no longer require the Saturday check-ins. We are allowing patients to be up to an hour from our center and plan to expand our access to include not only main campus but a regional site in the east and west markets.

To improve patient access, community oncology centers need outpatient programs with CRS prevention and careful timing of SUD to minimize additional resources.
Sandra Mazzoni, DO: BMS - Honoraria; GSK - Honoraria; Legend - Honoraria; J&J - Honoraria; Alexion - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Pfizer - Research Funding